Hagopian Arpi

Title: The Innovative Contributions of Hagopian Arpi

Introduction

Hagopian Arpi is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of vaccines. His work has implications for the treatment and prevention of hepatitis B virus-induced diseases.

Latest Patents

Hagopian Arpi holds a patent for "Vaccines comprising yeast-derived hepatitis B virus polypeptides." This patent describes a method where the entire hepatitis B virus pre-S antigen gene is linked in one contiguous reading frame to the hepatitis B virus surface antigen gene, expressed in Saccharomyces cerevisiae. The expressed protein aggregates into a particulate form that displays the major antigenic sites encoded by both domains. This highlights the utility of yeast as a host for the expression of pre-S domains. The protein developed through this process is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and infections.

Career Highlights

Hagopian Arpi is currently employed at Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to focus on innovative solutions in vaccine development, contributing to public health advancements.

Collaborations

Hagopian has collaborated with notable colleagues such as Ronald W. Ellis and Peter J. Kniskern. These collaborations have further enhanced the research and development efforts in the field of vaccine technology.

Conclusion

Hagopian Arpi's contributions to vaccine development, particularly in relation to hepatitis B, underscore his importance as an inventor in the biotechnology sector. His innovative work continues to have a lasting impact on public health and disease prevention.